0000000000583410

AUTHOR

Andrea Onetti-muda

0000-0002-0274-6178

showing 5 related works from this author

Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.

2016

11062Background: Human equilibrative nucleoside transporter 1 (hENT1) is the major gemcitabine transporter into cells. Gemcitabine is an active drug in different sarcoma subtypes including leiomyos...

LeiomyosarcomaDrugCancer Researchbiologybusiness.industrymedia_common.quotation_subjectTransporterEquilibrative nucleoside transporter 1medicine.diseaseGemcitabineOncologybiology.proteinCancer researchMedicineAngiosarcomaSarcomabusinessmedicine.drugmedia_commonJournal of Clinical Oncology
researchProduct

Deregulation of dicer and mir-155 expression in liposarcoma

2015

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versu…

MaleRibonuclease IIIPathologymedicine.medical_specialtyDEAD-box RNA Helicases -- biosynthesis -- genetics -- metabolismSettore MED/06 - Oncologia MedicaMicroRNAs -- biosynthesis -- geneticsAdipose tissueLiposarcomaRibonuclease III -- biosynthesis -- genetics -- metabolismDroshamiR-155DEAD-box RNA Helicasemir-155DEAD-box RNA HelicasesRetrospective StudiemicroRNAmedicineHumansMicroarray AnalysiDroshaRetrospective StudiesbiologySoft tissue sarcomaAnatomical pathologyMicroRNALiposarcomaSciences bio-médicales et agricolesmedicine.diseaseMicroarray AnalysisLiposarcoma -- genetics -- metabolism -- pathologyDicer; Drosha; liposarcoma; mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease IIIMicroRNAsOncologyliposarcomabiology.proteinlipids (amino acids peptides and proteins)FemaleClinical Research PaperDicerDicer; Drosha; Liposarcoma; Mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease III; OncologyHumanDicer
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

2020

Abstract Background SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage. We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection. Methods To understand the basis of th…

0301 basic medicineAdultMalelcsh:Immunologic diseases. AllergyImmunologyInflammationDiseaseAdaptive Immunitymedicine.disease_causeAntibodies ViralAsymptomaticSeverity of Illness IndexSerology03 medical and health sciences0302 clinical medicineImmune systeminnate and adaptiveimmune responsemedicineHumansImmunology and AllergyantibodiesNK cellOriginal ResearchCoronavirusB cellsbiologybusiness.industrySARS-CoV-2MonocyteSettore BIO/12COVID-19antibodies; B cells; COVID-19; innate and adaptiveimmune response; monocytes; NK cell; SARS-CoV-2Acquired immune systemImmunity InnateImmunoglobulin AKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunoglobulin MSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisImmunologybiology.proteinFemalemedicine.symptomAntibodybusinesslcsh:RC581-607monocytes
researchProduct